Intended for use as a control peptide when used with anti-NFkB p65 to block specific interaction of anti-NFkB p65 (p/n 100-4165) with the NFkB p65 RelA. NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IkB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkB-a. IkB-a binds to the p65 subunit, preventing nuclear localization and DNA binding. Low levels of p52 and p50 homodimers can also exist in cells.
序列
该【干冰】NFKB p65 (Rel A) N-TERMINAL SPECIFIC Peptide - 100-4165NP的详细信息查看Rockland提供的产品说明书。
来源宿主
该【干冰】NFKB p65 (Rel A) N-TERMINAL SPECIFIC Peptide - 100-4165NP的详细信息查看Rockland提供的产品说明书。
溶解建议
该【干冰】NFKB p65 (Rel A) N-TERMINAL SPECIFIC Peptide - 100-4165NP的详细信息查看Rockland提供的产品说明书。
保存建议
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
